Literature DB >> 23649689

Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia.

Kaweh Pars1, Niklas Garde, Thomas Skripuletz, Refik Pul, Reinhard Dengler, Martin Stangel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23649689     DOI： 10.1002/mus.23895

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  5 in total

1.  Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders.

Authors:  Min-Suk Yoon; Ralf Gold; Antonios Kerasnoudis
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

2.  Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases.

Authors:  Patrick Cherin; Abir Tadmouri; Christophe de Jaeger; Taylor Pindi Sala; Jean-Charles Crave
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-10-07       Impact factor: 5.346

3.  High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.

Authors:  Cherin Patrick; Delain Jean-Christophe; Crave Jean-Charles; Cartry Odile
Journal:  Case Rep Rheumatol       Date:  2014-07-16

4.  Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.

Authors:  Patrick Cherin; Jean-Christophe Delain; Christophe de Jaeger; Jean-Charles Crave
Journal:  Case Rep Neurol       Date:  2015-11-05

Review 5.  Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies.

Authors:  Andrea Farini; Chiara Villa; Luana Tripodi; Mariella Legato; Yvan Torrente
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.